UNSPSC 51352419: Mestranol/norethindrone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS200. This VA Drug Class (HS200) classifies this compound as belonging to the group CONTRACEPTIVES, SYSTEMIC.

UNSPSC 51352419 Mestranol/norethindrone, a Commodity code, encompasses oral contraceptive pharmaceutical products that state and local health agencies and cooperative purchasing organizations procure for distribution through public health systems, employee health plans, and multistate purchasing consortia. Recent solicitations show state health departments and multistate cooperative alliances acquiring these pharmaceuticals as part of broader generic and branded pharmaceutical procurement programs, either through direct-to-manufacturer arrangements or via established wholesaler networks with negotiated pricing structures. The issuing bodies include state health and human services commissions, multistate cooperative purchasing alliances administering agreements for multiple participating jurisdictions, and state procurement offices managing centralized pharmaceutical contracts for eligible public entities.

The Texas Health and Human Services Commission issued an RFI in April 2026 to explore direct-to-manufacturer prescription programs that could include specific pharmaceutical products like mestranol/norethindrone outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted an RFP in January 2026 with a March 26, 2026 response deadline to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon; the procurement requires vendors to supply through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) with awards effective July 1, 2026. Evaluation criteria for the MMCAP RFP weight price competitiveness at 75 percent, fixed pricing at 10 percent, EDI capability at 5 percent, and administrative compliance at 10 percent combined, with contract terms of two years for new vendors and extensions through June 30, 2028 for incumbents.